Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia

Jing Li; Volker H Haase; Chuan-Ming Hao

doi:10.1159/000527835

Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia

Kidney Dis (Basel). 2022 Oct 31;9(1):1-11. doi: 10.1159/000527835. eCollection 2023 Jan.

Authors

Jing Li¹, Volker H Haase^{2

3

4}, Chuan-Ming Hao¹

Affiliations

¹ Division of Nephrology, Huashan Hospital, Fudan University, Shanghai, China.
² Department of Medicine, Vanderbilt University Medical Center and Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
³ Department of Molecular Physiology & Biophysics and Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
⁴ Section of Integrative Physiology, Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.

Abstract

Background: Anemia is a common complication of chronic kidney disease. The hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is a new class of oral drugs for the treatment of renal anemia.

Summary: Clinical trials have consistently shown that HIF-PHIs can effectively increase hemoglobin in both the dialysis population and the nondialysis population. The effects of HIF-PHIs in treating renal anemia include promoting endogenous erythropoietin production and facilitating iron mobilization. Several studies suggest that the erythropoiesis effect of roxadustat is less affected by inflammation. Careful monitoring of thromboembolic events and tumor before and during HIF-PHI treatment is necessary.

Key messages: HIF-PHIs are effective in correcting renal anemia. The long-term safety of HIF-PHIs needs to be further studied.

Keywords: Anemia; Chronic kidney disease; Hypoxia-inducible factor; Iron.

Publication types

Review

Grants and funding

This research received no particular grant from any funding agency in the public, private, or not-for-profit sectors.